When did PHARMING GROUP NV (PHARM.AS) report earnings last quarter?
PHARMING GROUP NV (PHARM.AS) last reported earnings on 3/12/2026.
PHARMING GROUP NV (PHARM.AS) Earnings History & Surprises
AMS:PHARM • NL0010391025
Current stock price
1.353 EUR
+0.06 (+4.64%)
Last:
PHARM.AS Earnings overview
Past quarterly earnings results for PHARMING GROUP NV (PHARM.AS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.00
- Revenue Estimate
- 95.79M
Last Reported
Most Recent- Release Date
- Mar 12, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.01
- EPS Surprise
- 16.55%
- Revenue Surprise
- -1.71%
Beat Rate
Last 8 Quarters 50%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.01 | 0.01 | 16.55% | 100.00% | 106.5M | 108.35M | -1.71% | 14.92% |
| Q3 2025 | 0.01 | 0.00 | 1,070.87% | 600.00% | 97.3M | 96.233M | 1.11% | 30.00% |
| Q2 2025 | 0.01 | -0.03 | 123.30% | 400.00% | 93.2M | 85.758M | 8.68% | 25.79% |
| Q1 2025 | -0.02 | -0.02 | -42.39% | -15.79% | 79.094M | 69.767M | 13.37% | 42.29% |
| Q4 2024 | 0.01 | 0.01 | -27.22% | 225.00% | 92.672M | 83.166M | 11.43% | 14.10% |
| Q3 2024 | 0.00 | 0.00 | 22.33% | -140.00% | 74.849M | 79.238M | -5.54% | 12.28% |
| Q2 2024 | 0.00 | 0.01 | -124.27% | - | 74.093M | 76.668M | -3.36% | 34.97% |
| Q1 2024 | -0.02 | 0.01 | -363.52% | -11.76% | 55.586M | 70.478M | -21.13% | 30.66% |
| Q4 2023 | 0.00 | 0.01 | -138.83% | 80.00% | 81.217M | 74.933M | 8.39% | 48.69% |
| Q3 2023 | 0.01 | -0.03 | 118.67% | -61.54% | 66.661M | 63.18M | 5.51% | 22.90% |
| Q2 2023 | 0.00 | -0.01 | 100.00% | -100.00% | 54.897M | 54.363M | 0.98% | 9.47% |
| Q1 2023 | -0.02 | -0.01 | -153.92% | -440.00% | 42.541M | 49.595M | -14.22% | -8.74% |
| Q4 2022 | -0.02 | 0.01 | -430.23% | - | 54.621M | 61.724M | -11.51% | -72.53% |
| Q3 2022 | 0.01 | 0.00 | - | 1,201.69% | 54.238M | 55.62M | -2.48% | 2.60% |
| Q2 2022 | 0.00 | 0.01 | -61.66% | -66.78% | 50.146M | 53.198M | -5.74% | 0.95% |
| Q1 2022 | 0.01 | - | -62.26% | 46.617M | - | 18.92% | ||
| Q4 2021 | 0.00 | 0.00 | - | -100.00% | 198.871M | 57.508M | 245.81% | -6.27% |
| Q3 2021 | 0.00 | 0.00 | - | -110.09% | 52.864M | 55.686M | -5.07% | 14.62% |
| Q2 2021 | 0.01 | 0.02 | -30.05% | -21.87% | 49.673M | 69.371M | -28.40% | 26.40% |
| Q1 2021 | 0.01 | 0.01 | -7.25% | 9.23% | 39.199M | 63.237M | -38.01% | -20.48% |
| Q4 2020 | 0.02 | 0.01 | 76.63% | - | 212.174M | 62.49M | 239.53% | - |
| Q3 2020 | 0.01 | 0.02 | -40.11% | - | 46.121M | 56.991M | -19.07% | - |
| Q2 2020 | 0.02 | 0.02 | 2.61% | - | 39.299M | 59.743M | -34.22% | - |
| Q1 2020 | 0.01 | 0.02 | -38.37% | - | 49.294M | 54.624M | -9.76% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
281.14%
Max EPS beat (4)
1,070.87%
Min EPS beat (4)
-42.39%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
8.65%
Max Revenue beat (4)
13.37%
Min Revenue beat (4)
1.11%
Analysis
In the last 4 quarters, PHARM.AS has beaten EPS estimates in 2 out of 4 releases
PHARM.AS has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, PHARM.AS has beaten the EPS estimates by 281.1% on average.
In the last 4 quarters, PHARM.AS has beaten the revenue estimates by 8.6% on average.
Related analysis
PHARMING GROUP NV / PHARM.AS Earnings FAQ
Did PHARM stock beat earnings estimates in the most recent quarter?
PHARMING GROUP NV (PHARM.AS) beat EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often PHARMING GROUP NV beats earnings estimates?
In the last 4 quarters, PHARMING GROUP NV (PHARM.AS) has beaten EPS estimates in 2 out of 4 releases.